Dienogest for Treatment of Adenomyotic Uteri

Assiut University

Status

Completed

Conditions

Adenomyosis

Treatments

Radiation: Ultrasound

Drug: Gestodene-Ethinyl Estradiol

Drug: Dienogest group

Other: visual analogue scale

Study type

Interventional

Funder types

Other

Identifiers

NCT03890042

DAD

Details and patient eligibility

About

Adenomyosis is a common disease in women aged 40-50 years. It associates with dysmenorrhea and menorrhagia. Hysterectomy was considered the main treatment that could definitively cure this disease. Other treatment options are increasingly offered, including hormonal suppression with gonadotropin-releasing hormone agonists or danazol and endometrial ablation. However, deep adenomyosis responds weakly to the above treatment options, which are commonly not considered for long-term management because of the associated side effects.

Dienogest is a progestin medication which is used in birth control pills and in the treatment of endometriosis and adenomyosis. Low-dose combined oral contraceptive (COC) pills have been widely used as the primary treatment for menorrhagia. COCs can also be used to induce endometrial atrophy and to decrease endometrial prostaglandin production, which can consequently improve menorrhagia and dysmenorrhea that are associated with adenomyosis

Enrollment

100 patients

Sex

Female

Ages

20 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women aged 20-40 years
Women with ultrasonographic evidence of adenomyosis
Woman complains of vaginal bleeding or pelvic pain related to adenomyosis

Exclusion criteria

Women with a history of malignancy or histological evidence of endometrial hyperplasia
any adnexal abnormality on ultrasound
undiagnosed vaginal
contraindication to receive Vissane or gynera .